Hand-foot Syndrome Secondary to Low-dose Docetaxel in a Breast Cancer Patient

Kewan, Tariq; Alomari, Mohammad; Khazaaleh, Shrouq; Covut, Fahrettin; Olayan, May

doi:10.7759/cureus.4400

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Many dermatological adverse effects, including hand and foot syndrome, have been observed with routine chemotherapeutic agents used for managing various cancers. 7,8 Kwakman et al highlighted that systemic and topical treatments, dose reductions, and switching to other drugs in the same class may be different options for managing the hand-foot syndrome. However, prevention or early detection is key to managing this condition.…”

Section: Introductionmentioning

confidence: 99%

Drug-Induced Hand-Foot Syndrome in Cancer Patients Receiving Capecitabine in A Tertiary Care Hospital

Idrees¹,

Ahmad²,

Umair³

et al. 2023

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the frequency of hand-foot syndrome and associated factors among patients receiving Capecitabine for the management of cancer in a tertiary care setting. Study Design: Cross-sectional study. Place and Duration of Study: Oncology Department Combined Military Hospital, Rawalpindi Pakistan from Dec 2020 to May2021. Methodology: One hundred patients with malignant conditions taking Capecitabine for more than two weeks were included in the study. A detailed relevant dermatological examination was carried out on all the patients to diagnose hand-foot syndrome based on the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 Grading of Hand-Foot Syndrome. Results: Out of 100 cancer patients using Capecitabine for more than two weeks included in the study. Sixty-eight showed the presence of hand-foot syndrome, while 32 did not show any features of hand-foot syndrome. Combination treatment was statistically significantly associated with hand-foot syndrome among the patients included in our study (p-value<0.001). Conclusion: Hand-foot syndrome was a common side effect seen in patients managed with Capecitabine for their cancerous condition. Patients using other chemotherapeutic agents along with Capecitabine were more at risk of having hand-foot syndrome than those taking Capecitabine alone.

show abstract

Section: Introductionmentioning

confidence: 99%